(Q37401309)

20 August 2017

1 reference

title

Dapagliflozin: an emerging treatment option in type 2 diabetes (English)

1 reference

20 August 2017

0 references

Mark Kipnes

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

Expert Opinion on Investigational Drugs

20 August 2017

published in

1 reference

20 August 2017

volume

18

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

327-334

1 reference

Estimates of the cancer incidence and mortality in Europe in 2006.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

The decrease in breast-cancer incidence in 2003 in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Predicting the clinical status of human breast cancer by using gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Confirmation of a prognostic index in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Mechanisms of trastuzumab resistance and their clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Clinical application of the 70-gene profile: the MINDACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Comparison of prognostic gene expression signatures for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Concordance among gene-expression-based predictors for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

A multigenic program mediating breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Genes associated with breast cancer metastatic to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Genes that mediate breast cancer metastasis to lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530050902751618

10.1517/17530050902751618

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference